Immune checkpoint inhibitors have emerged as a pillar in the management of advanced
malignancies. However, nonspecific immune activation may lead to immune-related adverse …

Importance Immune checkpoint inhibitors (ICIs) have emerged as active therapies for a
variety of cancers. Cutaneous toxicities are common immune-related adverse events and …

Background Patients with cancer have an increased risk of complications from SARS-CoV-2
infection. Vaccination to prevent COVID-19 is recommended, but data on the …

Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …

Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid
organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and …

PURPOSE The aim of the current study was to report the efficacy of topical and systemic
treatments for immune-related cutaneous adverse events (ircAEs) attributed to checkpoint …

Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

Immune checkpoint blockade is therapeutically successful for many patients across multiple
cancer types. However, immune-related adverse events (irAE) frequently occur and can …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block key mediators of
tumor-mediated immune evasion. The frequency of its use has increased rapidly and has …

The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic
therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed …